Web Analytics
Abbvie inc annual report 2017



The measures set forth above were calculated as of December 31, 2017.

Catalysts to watch in 2018 and beyond are contained in this comment from Richard A. Gonzalez, the company's chairman and CEO: "We are poised to launch a ...

9 AbbVie: Company Overview

Financial Reports

AbbVie has Significantly Grown Revenue and EPS Since 2013

... Revenue Growth % Adjusted EPS Growth Total Shareholder Return ABBV Rank vs.

AbbVie Inc. Earnings Per Share

Source: 35 Annual J.P. Morgan Healthcare Conference, page 13. For 2017, AbbVie ...

financial analysis

(1): AbbVie's peer group above includes: Amgen, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, ...

Second Quarter 2016 AbbVie Financial Results Infographic

AbbVie Inc. (ABBV) Presents at 37th Annual J.P. Morgan Healthcare Conference - Slideshow

financial analysis abbvie

AbbVie Has Issues, But It Isn't the 'Next Big Drug Short'

AbbVie Inc. Posted 2nd Quarter Numbers

Top drugs by sales in 2017: Who sold the blockbuster drugs?

AbbVie has Significantly Grown Revenue and EPS Since 2013

However, the stock is valued at a significant premium to its historical average in the past five years (10-year data is not available, as AbbVie was not a ...


Humira Deaths Put AbbVie on FDA's Radar

AbbVie Inc. AbbVie Inc.

Annual Report 2018: State of the Bio Industry

AbbVie hopes Botox-maker Allergan can iron out its wrinkles

October 11, 2017 – We are pleased to offer our congratulations to Turnstone Biologics, a startup co-founded by FACIT, on the research, option and license ...



2017 GlaxoSmithKline Annual Report

Commenting on the Group's results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly ...

2016-2017 Annual Report Website

AbbVie Inc. Posted 2nd Quarter Numbers

AbbVie has passed along very high dividend growth since its spin-off from Abbott. In the past four years, dividends are up 60%, including a strong 12% raise ...


Source: 2017 AbbVie Strategic Update, ...

Morgan Stanley Healthcare Conference presentation slide. Source: AbbVie.

BSPS career destinations

21% Of AbbVie Inc (ABBV) Shareholders Want To Know How Drug Pricing Is Integrated Into Incentive Programs

To view our annual report, use the left and right arrow buttons below to read our annual report, or download a PDF version here.

Corporate governance 61 Nationality American executive director of AbbVie Inc. ident of Melody Meyer Energy LLC or Advisor Cairn to India Limited tee of ...


2017-2018 Annual Report Interactive PDF

BP Annual Report and Form 20-F 201764 Professor Dame Ann Dowling Independent non-executive director Tenure Appointed 3 February 2012 Board and committee ...

Biopharmaceuticals Contract Manufacturing Market

Chart of AbbVie Inc. (NYSE:ABBV)

1 Discussion Materials February 28, 2017 By: Gautam Singh Karan Dhir

To view our annual report, use the left and right arrow buttons below to read our annual report, or download a PDF version here.

AbbVie's 4% Dividend Yield Continues Outperforming Peer Averages (ABBV)

AbbVie ABBV Stock: 4Q2018 Dividend Safety Update

2016 Annual Report

AnnualReport2018_cover only.jpg

AbbVie is buying Allergan after a slump in shares in recent years

AbbVie, Johnson & Johnson Lead US Immunology Drug Market Due to High Cost of Biologic Treatments

Download Full Size ...

It's a story about Hope.

30/05/2017 1 • aTop ten performing pharmaceutical companies by global sales bSource ...

2017 Annual Report

Commenting on the Group's results, Roche CEO Severin Schwan said: “In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions ...

Source: 2017 AbbVie Strategic Update, ...

... Insights analyzes and forecasts the Interleukin-2 Market at both global and regional level. The report provides an analysis of 6 years, in which 2017 ...

AbbVie Inc (ABBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report

Merck's Be Well Logo

NOTES FOR NUCLEAR SCIENCE NERDS EvaluatePharma reports ...

Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis

2017 AAN Annual Meeting Science Program

KGaA Annual Report 2018

Page 20

EXHIBIT 99.1. Picture 3. Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results


In 2017, AbbVie was slammed by the US Food and Drug Administration (FDA) for improper handling of death complaints relating to Humira. Credit: AbbVie .

AbbeVie is a MoneyShow.com 2019 Top Pick. Here, AbbVie's signature drug Humira

Biogen and Abbvie Take Multiple Sclerosis Drug Off Market

Several of the most threatening biosimilar developers have essentially capitulated by signing deals with AbbVie that delay their U.S. market entry until ...


Our Annual and Integrated Report 2018-19

AbbVie 2015 annual report 2. Pharmacyclics December 2014 Investor Presentation 3. imbruvica.com 4. AbbVie and Johnson & Johnson 2017 annual reports  Abex ...

Allergan Reports First Quarter 2019 Financial Results

A man, seen from behind, scratches his head as he looks at arrows pointing

AbbVie (ABBV) Presents At 35th Annual J.P. Morgan Healthcare Conference

Mavyret has turned around the fortunes of AbbVie's HCV portfolio in the past year, pushing total sales up to nearly $1.9 billion in the first six months of ...


NYSE:ABBV Last Perf Sep 22nd 17

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results

AbbVie to Post 4th-Quarter Numbers